ORGANISMO AUTONOMO INSTITUTO DE SALUD PUBLICA Y LABORAL DE NAVARRA

Their core work

The Instituto de Salud Pública y Laboral de Navarra is the regional public health and occupational health authority for the Navarre region of Spain. Their core operational work involves epidemiological surveillance of infectious diseases, running sentinel networks that collect clinical and virological data from primary care centres and hospitals across Navarra. In EU research, they function as a contributing surveillance site — feeding regional Spanish data into large pan-European studies on vaccine effectiveness and respiratory disease burden. They bridge the regional health system (GPs, hospitals, labs) with multinational research consortia, providing the real-world evidence base that makes pooled European epidemiology possible.

What they specialise in

How they've shifted over time

Their first project (I-MOVE-plus, 2015–2018) focused narrowly on measuring influenza vaccine effectiveness across Europe — a long-running European platform that pre-dates H2020. Their second project (I-MOVE-COVID-19, 2020–2022) applied the same surveillance infrastructure and methodological toolkit to the COVID-19 pandemic, adding primary care networks, hospital networks, treatment evaluation, and virological surveillance as explicit scope areas. The trajectory is clear: they started as a seasonal influenza surveillance node and evolved into a broader respiratory pathogen monitoring site capable of rapid pivot to emerging infectious disease threats. Note that early-period keywords are absent from the data, so this evolution is inferred partly from project titles and the sharp keyword expansion in the recent period.

They are building toward a standing capacity for rapid-response surveillance of any respiratory pathogen — positioning themselves as a reusable regional data node for future European pandemic preparedness networks.

How they like to work

This organisation exclusively joins as a consortium participant and has never led an H2020 project, consistent with their role as a regional data provider rather than a research coordinator. Despite only two projects, they have accumulated 44 unique partners across 19 countries — numbers typical of large European surveillance platforms where many national and regional sites contribute to a shared study design. This suggests they are comfortable operating inside large, tightly coordinated multi-site consortia where protocols are set centrally and sites execute locally.

Their two projects generated connections with 44 partners in 19 countries, an unusually broad network for such a small project count — reflecting participation in pan-European surveillance platforms that inherently involve many national nodes. The network is strongly European in character, spanning both Western and Eastern EU member states.

What sets them apart

Among Spanish participants in European health research, this organisation occupies a specific niche as a regional public authority with both the institutional mandate and operational infrastructure (sentinel GP practices, hospital labs) to generate population-level surveillance data — something university groups typically cannot offer. Their consistent presence in the I-MOVE network across two funding cycles (pre-COVID and COVID) signals that pan-European surveillance consortia regard them as a reliable, technically competent contributing site. For a consortium needing credible Spanish regional data for a respiratory disease or vaccine study, they are one of a small number of Spanish public health authorities with demonstrated EU research experience.

Highlights from their portfolio

• I-MOVE-plus
  The larger of the two grants (EUR 236,250) and part of the long-running I-MOVE platform — Europe's primary infrastructure for measuring seasonal influenza vaccine effectiveness — giving this organisation a direct link to a well-established European epidemiology network.
• I-MOVE-COVID-19
  Demonstrates their ability to rapidly redeploy existing surveillance infrastructure for a novel pathogen, expanding scope to include treatment evaluation and hospital networks alongside the established primary care sentinel model.